Company profile for Biofrontera

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Biofrontera Inc. is a pharmaceutical company, specializing in high quality dermatological products for the care and treatment of skin diseases. Biofrontera’s primary focus is on the development and commercialization of novel therapies for non-melanoma skin cancer. The entire team at Biofrontera consists of highly motivated and exceptionally committed people, aiming to provide high quality products and great service for docto...
Biofrontera Inc. is a pharmaceutical company, specializing in high quality dermatological products for the care and treatment of skin diseases. Biofrontera’s primary focus is on the development and commercialization of novel therapies for non-melanoma skin cancer. The entire team at Biofrontera consists of highly motivated and exceptionally committed people, aiming to provide high quality products and great service for doctors and their patients. Biofrontera headquarters are located in Leverkusen, Germany, and Biofrontera Inc. has its offices near Boston, MA.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
201 Edgewater Dr Ste 210 Wakefield, MA 01880
Telephone
Telephone
1-844-426-3589
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/13/3187324/0/en/Biofrontera-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Provides-a-Business-Update.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183608/0/en/Biofrontera-Inc-announces-sale-of-license-to-Xepi-Antibiotic-Cream-to-Pelthos-Therapeutics-Inc-for-up-to-10M.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3183042/0/en/Biofrontera-Inc-to-Report-Third-Quarter-2025-Financial-Results-on-November-12-2025-and-Host-a-Conference-Call-on-November-13-2025.html

GLOBENEWSWIRE
06 Nov 2025

https://www.globenewswire.com/news-release/2025/10/23/3172054/0/en/Biofrontera-Inc-Closes-Purchase-of-All-Ameluz-and-RhodoLED-US-Assets-from-Biofrontera-AG.html

GLOBENEWSWIRE
23 Oct 2025

https://www.globenewswire.com/news-release/2025/09/26/3157049/0/en/Biofrontera-Inc-to-Participate-in-the-Lytham-Partners-Fall-2025-Investor-Conference-on-September-30-2025.html

GLOBENEWSWIRE
26 Sep 2025

https://www.globenewswire.com/news-release/2025/09/16/3150998/0/en/Biofrontera-Inc-Announces-Last-Patient-Out-in-Phase-3-Study-of-Ameluz-aminolevulinic-acid-HCI-Topical-Gel-10-Photodynamic-Therapy-PDT-for-the-Treatment-of-Actinic-Keratoses-AK-on-t.html

GLOBENEWSWIRE
16 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty